Upgrade to SI Premium - Free Trial

UBS Cuts Price Target on Horizon Pharma (HZNP) After Meeting with Management

April 13, 2016 8:20 AM
UBS maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $24.00 (from $39.00), after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change

Next Articles